FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2489012263> ?p ?o ?g. }

• W2489012263 abstract "Background: Massive parallel sequencing is a promising tool to investigate key molecular events in cancer. Genomic alterations, such as PIK3CA mutations, are important for response to therapy in HER2+ breast cancer (BC). We have investigated genomic alterations in 364 pretherapeutic core biopsies from two prospective clinical trials with or without anti-HER2 therapy. Methods: A total of 417 formalin-fixed paraffin embedded samples from HER2+ tumors of the neoadjuvant GeparTrio (G3 without anti-HER2 treatment) and GeparSepto (G7 with dual blockade and randomization for paclitaxel vs nab-paclitaxel) study were analyzed by deep targeted massive parallel sequencing, which was successful in 364 tumors (87%). We interrogated hot spot regions of 22 genes (including TP53, PIK3CA, CDH1, FBXW7, PTEN, AKT1, ATM, BRAF, EGFR, ESR1, FGFR2, HRAS, KRAS, NRAS, SF3B1) with a minimum coverage of 500. Only non-synonymous mutations with allele frequencies ≥10% were taken into consideration. Results: A total of 291 non-synonymously mutated genes were detected in the 364 tumor samples, the most commonly mutated genes were TP53 (47%), and PIK3CA (24%), respectively. EGFR, KRAS, NRAS, HRAS were combined to the XRAS group with 9 (2.5%) mutations. 151 tumors had no, 148 one, 57 two, and 8 tumors three or more mutated genes. There were no statistical significant differences between HR+ and HR- HER2+ tumors; overall 141/252 HR+ and 72/112 HR- tumors had a mutation. HR+ tumors had TP53 mutations in 112/252 (44.4%); PIK3CA mutations in 53/252 (21.0%) and XRAS mutations in 5/252 (2.0%). HR- tumors had 60/112 (53.6%) TP53 mutations, 34/112 (30.4%) PIK3CA mutations and 4/112 (3.6%) xRAS mutations. Response rates (pCR, ypT0 ypN0) were evaluated separately for the two trials. In G7 the pCR rate was 64.7% in the group with a TP53 mutation vs 60.6% in the group without (p = 0.545). The pCR rate was significantly lower in the PIK3CA mutant vs wild type (wt) group (47.7% vs 66.7%; p = 0.009). This effect was seen in the HR+ (43.9% vs 61.3%; p = 0.052) and the HR- cohort (54.2% vs 80.0%; p = 0.029). In the nab-paclitaxel cohort, pCR rates were significantly lower in patients with PIK3CA mutations compared to those without (38.7% vs. 72.0%; p = 0.001), whereas in the paclitaxel group, there was no significant difference between patients with and without PIK3CA mutations (55.9% vs. 60.9%; p = 0.690; interaction p = 0.039). Neither TP53 nor xRAS mutations showed a significant effect on response and treatment effect. In G3 the pCR rate was 16.3% in the PIK3CA wt cohort compared to 23.7% in the mutant cohort; p = 0.339. Conclusion: Targeted NGS on FFPE core biopsies reliably identified the most common genomic alterations in HER+ BC. PIK3CA mutation in HER2+ BC predicts resistance to anti-HER2 therapy. PIK3CA mutations were found to be predictive for response to nab-paclitaxel in G7. The results show that mutational alterations are relevant for response in HER2+ BC. Citation Format: Sibylle Loibl, Jan Budczies, Wilko Weichert, Jenny Furlanetto, Albrecht Stenzinger, Nicole Pfarr, Gunter von Minckwitz, Christian Jackisch, Andreas Schneeweiss, Peter A. Fasching, Sabine Schmatloch, Bahriye Aktas, Valentina Nekljudova, Karsten Weber, Michael Untch, Carsten Denkert carsten.denkert@charite.de. Prediction of therapy resistance by targeted massive-parallel sequencing in primary HER2-positive breast cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 5010." @default.
• W2489012263 created "2016-08-23" @default.
• W2489012263 creator A5011410319 @default.
• W2489012263 creator A5014883814 @default.
• W2489012263 creator A5016987068 @default.
• W2489012263 creator A5017728105 @default.
• W2489012263 creator A5018744564 @default.
• W2489012263 creator A5026607584 @default.
• W2489012263 creator A5040331693 @default.
• W2489012263 creator A5043793453 @default.
• W2489012263 creator A5054109395 @default.
• W2489012263 creator A5057181684 @default.
• W2489012263 creator A5068818204 @default.
• W2489012263 creator A5077307794 @default.
• W2489012263 creator A5087559224 @default.
• W2489012263 creator A5089035898 @default.
• W2489012263 creator A5089392438 @default.
• W2489012263 date "2016-07-15" @default.
• W2489012263 modified "2023-09-30" @default.
• W2489012263 title "Abstract 5010: Prediction of therapy resistance by targeted massive-parallel sequencing in primary HER2-positive breast cancer" @default.
• W2489012263 doi "https://doi.org/10.1158/1538-7445.am2016-5010" @default.
• W2489012263 hasPublicationYear "2016" @default.
• W2489012263 type Work @default.
• W2489012263 sameAs 2489012263 @default.
• W2489012263 citedByCount "1" @default.
• W2489012263 countsByYear W24890122632018 @default.
• W2489012263 crossrefType "proceedings-article" @default.
• W2489012263 hasAuthorship W2489012263A5011410319 @default.
• W2489012263 hasAuthorship W2489012263A5014883814 @default.
• W2489012263 hasAuthorship W2489012263A5016987068 @default.
• W2489012263 hasAuthorship W2489012263A5017728105 @default.
• W2489012263 hasAuthorship W2489012263A5018744564 @default.
• W2489012263 hasAuthorship W2489012263A5026607584 @default.
• W2489012263 hasAuthorship W2489012263A5040331693 @default.
• W2489012263 hasAuthorship W2489012263A5043793453 @default.
• W2489012263 hasAuthorship W2489012263A5054109395 @default.
• W2489012263 hasAuthorship W2489012263A5057181684 @default.
• W2489012263 hasAuthorship W2489012263A5068818204 @default.
• W2489012263 hasAuthorship W2489012263A5077307794 @default.
• W2489012263 hasAuthorship W2489012263A5087559224 @default.
• W2489012263 hasAuthorship W2489012263A5089035898 @default.
• W2489012263 hasAuthorship W2489012263A5089392438 @default.
• W2489012263 hasConcept C104317684 @default.
• W2489012263 hasConcept C1167327 @default.
• W2489012263 hasConcept C121608353 @default.
• W2489012263 hasConcept C126322002 @default.
• W2489012263 hasConcept C143998085 @default.
• W2489012263 hasConcept C190283241 @default.
• W2489012263 hasConcept C21790070 @default.
• W2489012263 hasConcept C2777609662 @default.
• W2489012263 hasConcept C2777983448 @default.
• W2489012263 hasConcept C2781187634 @default.
• W2489012263 hasConcept C2781230642 @default.
• W2489012263 hasConcept C501734568 @default.
• W2489012263 hasConcept C502942594 @default.
• W2489012263 hasConcept C526805850 @default.
• W2489012263 hasConcept C530470458 @default.
• W2489012263 hasConcept C54355233 @default.
• W2489012263 hasConcept C71924100 @default.
• W2489012263 hasConcept C86554907 @default.
• W2489012263 hasConcept C86803240 @default.
• W2489012263 hasConceptScore W2489012263C104317684 @default.
• W2489012263 hasConceptScore W2489012263C1167327 @default.
• W2489012263 hasConceptScore W2489012263C121608353 @default.
• W2489012263 hasConceptScore W2489012263C126322002 @default.
• W2489012263 hasConceptScore W2489012263C143998085 @default.
• W2489012263 hasConceptScore W2489012263C190283241 @default.
• W2489012263 hasConceptScore W2489012263C21790070 @default.
• W2489012263 hasConceptScore W2489012263C2777609662 @default.
• W2489012263 hasConceptScore W2489012263C2777983448 @default.
• W2489012263 hasConceptScore W2489012263C2781187634 @default.
• W2489012263 hasConceptScore W2489012263C2781230642 @default.
• W2489012263 hasConceptScore W2489012263C501734568 @default.
• W2489012263 hasConceptScore W2489012263C502942594 @default.
• W2489012263 hasConceptScore W2489012263C526805850 @default.
• W2489012263 hasConceptScore W2489012263C530470458 @default.
• W2489012263 hasConceptScore W2489012263C54355233 @default.
• W2489012263 hasConceptScore W2489012263C71924100 @default.
• W2489012263 hasConceptScore W2489012263C86554907 @default.
• W2489012263 hasConceptScore W2489012263C86803240 @default.
• W2489012263 hasLocation W24890122631 @default.
• W2489012263 hasOpenAccess W2489012263 @default.
• W2489012263 hasPrimaryLocation W24890122631 @default.
• W2489012263 hasRelatedWork W1537747962 @default.
• W2489012263 hasRelatedWork W2046687780 @default.
• W2489012263 hasRelatedWork W2054536628 @default.
• W2489012263 hasRelatedWork W2067582244 @default.
• W2489012263 hasRelatedWork W2067806638 @default.
• W2489012263 hasRelatedWork W2104659222 @default.
• W2489012263 hasRelatedWork W2132468839 @default.
• W2489012263 hasRelatedWork W2317743587 @default.
• W2489012263 hasRelatedWork W2591811736 @default.
• W2489012263 hasRelatedWork W2592290895 @default.
• W2489012263 hasRelatedWork W2800609989 @default.
• W2489012263 hasRelatedWork W2936680421 @default.
• W2489012263 hasRelatedWork W2940852996 @default.
• W2489012263 hasRelatedWork W3005634963 @default.
• W2489012263 hasRelatedWork W3005733131 @default.
• W2489012263 hasRelatedWork W3006571870 @default.
• W2489012263 hasRelatedWork W3037275467 @default.

• next